Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05276622 · ClinicalTrials.gov registry record

Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)

A clinical trial, sponsored by UNC Lineberger Comprehensive Cancer Center.

Terminated
Registry status
64
Enrollment target

NCT05276622: Clinical Trial study, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT05276622 is a clinical trial that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05276622 was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.

TERMINATED
Registry status
64 participants
Enrollment target

Study Summary

This research study is explore the impact over time of multiple myeloma and its associated treatments on the physical and cognitive function and quality of life of patients and their care partners and how these impacts affect the overall illness experience.

Primary Outcome

Standardized National Institutes of Health Toolbox Cognition Battery (objective) (NIHTB-CB) will be used for the measure of cognitive function. The NIHTB-CB contains 7 computer-based instruments assessing 5 cognitive sub-domains: Language, Executive Function, Episodic Memory, Processing Speed, and Working Memory. The Composite Score is calculated using all subsets. Higher score =better level of cognitive functions.

Interventions

  • OTHER Comprehensive Geriatric Assessment
  • OTHER Qualitative patient-care partner interviews
  • OTHER Surveys on well-being and function

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2022-02-08
Est. Completion 2023-10-03

Why NCT05276622 stopped before completion

NCT05276622 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.

The record links to 0 conditions, and to 3 interventions - of which Comprehensive Geriatric Assessment is the first listed.

NCT05276622 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05276622 about?

NCT05276622 is a clinical study titled "Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)". This research study is explore the impact over time of multiple myeloma and its associated treatments on the physical and cognitive function and quality of life of patients and their care partners and how these impacts affect the overall illness experience.

What is the current status of trial NCT05276622?

This trial is currently terminated. The enrollment target is 64 participants. The study started on 2022-02-08. Estimated completion is 2023-10-03.

What interventions are being tested in trial NCT05276622?

The interventions under investigation include: Comprehensive Geriatric Assessment (OTHER), Qualitative patient-care partner interviews (OTHER), Surveys on well-being and function (OTHER).

Who is sponsoring clinical trial NCT05276622?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05276622, the US trial registry maintained by the National Library of Medicine. NCT05276622 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.